Endocrine-disrupting chemicals: what the 2026 UNEP/WHO report means for industry
Updated: 14 minutes ago
The United Nations Environment Programme (UNEP) and the World Health Organization (WHO) have released their new report, State of the Science of Endocrine-Disrupting Chemicals 2026. More than a decade after the previous assessment, this publication provides an important update on the scientific understanding of endocrine disruption (ED), its impacts on human health and the environment, and the limitations of existing assessment methodologies.
For industry, these scientific developments highlight the importance of anticipating potential regulatory challenges and adopting a more proactive approach to chemical safety assessment.
Endocrine-disrupting chemicals: a growing body of scientific evidence
Since the 2012 assessment, scientific evidence linking endocrine-disrupting chemicals (EDCs) to adverse effects has substantially strengthened. Research has expanded our understanding of the potential impacts of endocrine disruption, including effects on reproductive health, neurodevelopment, metabolism and wildlife.
These advances raise important questions about the ability of conventional testing and assessment strategies to adequately identify endocrine-disrupting properties.
Moving beyond conventional endocrine disruptor testing
Regulatory testing has traditionally focused on four main endocrine modalities, commonly referred to as EATS:
Estrogen
Androgen
Thyroid
Steroidogenesis
While these modalities remain essential to endocrine disruptor assessment, they do not capture the full complexity of the endocrine system.
Other hormonal pathways, critical windows of exposure, non-monotonic dose-response relationships and combined exposures represent additional challenges for conventional assessment approaches. These considerations reinforce the need for broader and more integrated assessment strategies.
The growing role of New Approach Methodologies (NAMs)
New Approach Methodologies (NAMs) offer valuable opportunities to improve the identification and assessment of potential endocrine-disrupting properties.
Through in vitro assays, in silico predictions and mechanistic investigations, these approaches can support substance screening, prioritisation and the identification of data gaps.
However, negative NAM results alone cannot rule out endocrine-disrupting properties.
Understanding the biological relevance, applicability and limitations of each methodology remains essential when drawing conclusions.
Strengthening endocrine disruptor assessment through Weight of Evidence
An integrated Weight-of-Evidence (WoE) approach can support a more comprehensive understanding of a substance’s potential endocrine-disrupting properties.
Depending on the available information, such an assessment may combine:
Regulatory toxicological and ecotoxicological studies;
Scientific and academic literature;
New Approach Methodologies (NAMs);
Adverse Outcome Pathways (AOPs);
In silico predictions and read-across;
Cross-species evidence.
Grouping and read-across approaches can also help anticipate potential concerns across chemical families, support data gap assessment and reduce the risk of regrettable substitution, where a substance of concern is replaced by another with similar hazardous properties.
What does the 2026 UNEP/WHO report mean for industry?
Although the report does not introduce new regulatory obligations in itself, its findings are particularly relevant in the context of evolving chemical regulatory frameworks, including REACH and CLP.
Rather than waiting for regulatory developments to affect their substances, companies can benefit from proactively reviewing their chemical portfolios.
This may involve:
Screening substances for potential endocrine-disrupting properties;
Reviewing existing toxicological and ecotoxicological data;
Identifying data gaps and emerging scientific concerns;
Assessing potential alternatives to substances of concern;
Developing targeted and scientifically justified testing strategies.
Early anticipation can help companies better manage regulatory uncertainties, optimise testing resources and support informed decisions throughout the product life cycle.
How CEHTRA can support your endocrine disruptor assessment
At CEHTRA, our experts combine scientific and regulatory expertise with innovative digital tools to help companies identify, assess and anticipate potential endocrine disruption concerns in a stepwise and efficient way.
Our approach integrates:
Scientific literature and regulatory data review;
Proactive substance and portfolio screening;
In silico approaches and read-across;
Weight-of-Evidence assessment;
Data gap analysis;
Targeted testing strategies.
By making the best use of existing scientific evidence, we help companies develop assessment strategies tailored to their substances and regulatory requirements.
Better assessment does not necessarily mean more testing. It means making better use of all available evidence.
Do you want to anticipate endocrine disruption concerns within your chemical portfolio?
Contact our experts to discuss your assessment strategy.
Reference
UNEP/WHO (2026) – State of the Science of Endocrine-Disrupting Chemicals 2026



